CAR-T-Therapie

CAR-T therapy engineers T cells to attack cancer; focus on auto/allo and targets.The sector's total market cap is 1563.49 billion USD, with a 24h change of +1.37%. Among 7 constituents, 7 are up (100.00%) and 0 are down (0%). The top gainer is Gilead Sciences Inc (GILD), with a 24h increase of +1.83%.CAR-T steady; breadth mixed. Favor leaders; be selective.
Name
Letzter Preis
Änderung %
Letzter Preis / Änderung %
Chart
Price Range
Aktion
JNJ
JNJJohnson & Johnson
268,23$268,23
+1,82 %+$4,81
268,23
+1,82 %
$262,43$268,23
AMGN
AMGNAmgen Inc
377,32$377,32
+0,34 %+$1,28
377,32
+0,34 %
$375,59$381,60
PFE
PFEPfizer Inc.
24,77$24,77
+0,91 %+$0,23
24,77
+0,91 %
$24,55$24,83
GILD
GILDGilead Sciences Inc
131,63$131,63
+1,77 %+$2,30
131,63
+1,77 %
$129,33$132,51
NVS
NVSNovartis AG
156,55$156,55
+1,00 %+$1,55
156,55
+1,00 %
$154,89$157,59
INCY
INCYIncyte Genomics Inc
119,26$119,26
+1,35 %+$1,59
119,26
+1,35 %
$117,57$120,00
GSK
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)
52,13$52,13
+1,51 %+$0,78
52,13
+1,51 %
$51,21$52,47